Although they did not show antifibrotic effects in several fibrotic diseases, such as idiopathic pulmonary fibrosis and systemic sclerosis, in our in vitro models, prednisone and methylprednisolone were able to counteract the increase of collagen I and α-SMA expression in TGF-β1-treated CCD-18Co cells at both doses tested, while budesonide significantly counteracted these effects induced by TGF-β1 only at the highest dose. The gene discussed is ACTA1; the disease is systemic sclerosis.